French Telemonitoring Study Reveals Diabetes Impact on Heart Failure Survival — Insights for Australian Clinicians

References

1. 1.Satelia. (2024). Impact of Diabetes, Short-term Weight Variability, Heart Failure Etiologies and Other Comorbidities on Survival in a National Telemonitored Heart Failure Cohort. ClinicalTrials.gov. NCT07561866. https://clinicaltrials.gov/study/NCT07561866
2. 2.Dunlay, S. M., Givertz, M. M., Aguilar, D., Allen, L. A., Chan, M., Desai, A. S., Deswal, A., Dickson, V. V., Kosiborod, M. N., Lekavich, C. L., McCoy, R. G., Mentz, R. J., & Yancy, C. W. (2019). Type 2 diabetes mellitus and heart failure: a scientific statement from the American Heart Association and the Heart Failure Society of America. Circulation, 140(7), e294-e324. https://doi.org/10.1161/CIR.0000000000000691
3. 3.Kristensen, S. L., Preiss, D., Jhund, P. S., Squire, I., Cardoso, J. S., Merkely, B., Martinez, F., Starling, R. C., Desai, A. S., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., Zile, M. R., McMurray, J. J., & Packer, M. (2016). Risk related to pre-diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: insights from prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial. Circulation: Heart Failure, 9(1), e002560. https://doi.org/10.1161/CIRCHEARTFAILURE.115.002560
4. 4.Inglis, S. C., Clark, R. A., Dierckx, R., Prieto-Merino, D., & Cleland, J. G. (2015). Structured telephone support or non-invasive telemonitoring for patients with heart failure. Cochrane Database of Systematic Reviews, (10), CD007228. https://doi.org/10.1002/14651858.CD007228.pub3
5. 5.Koehler, F., Koehler, K., Deckwart, O., Prescher, S., Wegscheider, K., Kirwan, B. A., Winkler, S., Vettorazzi, E., Bruch, L., Oeff, M., Zugck, C., Doerr, G., Naegele, H., Störk, S., Butter, C., Sechtem, U., Angermann, C., Gola, G., Prondzinsky, R., ... Anker, S. D. (2018). Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2): a randomised, controlled, parallel-group, unmasked trial. The Lancet, 392(10152), 1047-1057. https://doi.org/10.1016/S0140-6736(18)31880-4
6. 6.MacDonald, M. R., Petrie, M. C., Varyani, F., Ostergren, J., Michelson, E. L., Young, J. B., Solomon, S. D., Granger, C. B., Swedberg, K., Yusuf, S., Pfeffer, M. A., & McMurray, J. J. (2008). Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Heart Journal, 29(11), 1377-1385. https://doi.org/10.1093/eurheartj/ehn153